SET antibody Phosphatase 2A Inhibitor I2PP2A - Blocking Peptide

Many awards

The Blocking Peptides we offer receive many awards.

Best practices

Systematic production of Activating Antibody ensuring their high quality.

Big trust

To this day, many customers have trusted us and our Antibody products.


50 μg

Catalog no.



168 EUR





Antibody's reacts with


Antibody is raised in




Protein number

see ncbi

French translation



Western Blot


not specified

Antibody's specificity

No Data Available


Proteins & Peptides

Antibody's reacts with these species

This antibody doesn't cross react with other species

Antibody come from

Synthetic peptide derived from the human STC-1 protein.

Antibody's suited for

Optimal concentration should be evaluated by serial dilutions.

Antigen-antibody binding interaction

SET antibody Phosphatase 2A Inhibitor I2PP2A - Blocking Peptide

Other description

Provided as solution in phosphate buffered saline with 0.08% sodium azide.


You can block the antibody by the specific target amino acid sequence of peptide.


If you buy Antibodies supplied by nordc they should be stored frozen at - 24°C for long term storage and for short term at + 5°C.blocking peptide


This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals. This datasheet is as accurate as reasonably achievable, but Nordic-MUbio accepts no liability for any inaccuracies or omissions in this information.

Relevant references

1. Jeffrey K.J., Reddel R.R., 'Characterization of the human stanniocalcin 1 gene._x000B_Submitted (MAR-2000) to the EMBL/GenBank/DDBJ databases_x000B__x000B_2. Olsen H.S., Cepeda M.A., Zhang Q.-Q., Rosen C.A., Vozzolo B.L., Wagner G.F., Human stanniocalcin: a possible hormonal regulator of mineral metabolism._x000B_Proc. Natl. Acad. Sci. U.S.A. 93:1792-1796(1996) [PubMed: 8700837] [Abstract]

Long description

Human SET was originally identified as part of the SET-CAN fusion gene produced by a somatic translocation event in a patient with acute undifferentiated leukemia. In developing kidney, SET is highly expressed in the zone of nephron morphogenesis. SET has been shown to be a potent and specific inhibitor of protein phosphatase 2A, a family of major serine/threonine phosphatases involved in regulating cell proliferation and differentiation. SET is also involved in the regulation of renal cell proliferation and tumorigenesis. SET mRNA expression is markedly reduced in cells rendered quiescent by serum starvation, contact inhibition, or differentiation. SET protein expression is also much greater in developing rat and human kidney than in fully differentiated, mature kidney. High levels of SET mRNA and SET protein expression arefound in Wilms' tumor, but not in renal cell carcinoma, adult polycystic kidney disease or in transitional cell carcinoma.


Tissue, pathway, proteinase, peptidase, protease ,acrosin, lipoprotein, activator, caspase, trypsin, papain, esterase inhibitors are proteins or receptor ligands or receptor antagonists that bind to an enzyme receptor and decreases its activity. Since blocking an enzyme's activity can kill a pathogen or correct a metabolic imbalance, many drugs are enzyme inhibitors. Not all receptor antagonist that bind to enzymes are inhibitors; enzyme activator ligands or agonists bind to enzymes and increase their enzymatic activity, while enzyme substrates bind and are converted to products in the normal catalytic cycle of the enzyme.Peptides short amino acid chains or epitopes or blocking antagonists. The shortest peptides are dipeptides, consisting of 2 amino acids joined by a single peptide bond, followed by tripeptides, tetra peptides, ... till polypeptides that are long, continuous, and unbranched synthetic peptide chains. These biological oligomers and polymers can be Solid-phase peptide synthesis (SPPS), or in continue produced for custom peptide synthesis projects. The High-efficiency solid phase peptide synthesis (HE-SPPS) is give very low production costs.